{$CCL}

Moderna оценила эффективность вакцины от COVID в 100% при тяжелых случаях. 📢📢🔝🔝 Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization November 30, 2020 at 6:59 AM EST PDF Version Primary efficacy analysis of the Phase 3 COVE study of mRNA-1273 involving 30,000 participants included 196 cases of COVID-19, of which 30 cases were severe Vaccine efficacy against COVID-19 was 94.1%; vaccine efficacy against severe COVID-19 was 100% mRNA-1273 continues to be generally well tolerated; no serious safety concerns identified to date Phase 3 COVE Study has exceeded 2 months of median follow-up post vaccination as required by the U.S. FDA for Emergency Use Authorization (EUA) Moderna plans today to request EUA from the U.S. FDA, to apply for a conditional marketing authorization with the European Medicines Agency (EMA) and to progress with the rolling reviews, which have already been initiated with international regulatory agencies #новости #пандемия #короновирус #вакцина $AAPL $TSLA $M {$CCL} $CNK